Registering a medicinal product in the UEMOA region

1. Regional regulatory framework

Each member state has a national pharmaceutical regulatory authority (ANRP) empowered to grant Marketing Authorisation (MA). UEMOA community decisions set shared requirements for dossier composition, inspections and good practices.

The process remains largely national to date: an MA obtained in Senegal does not automatically open the Ivorian or Burkinabè market. Harmonisation efforts, including mutual recognition, are ongoing.

2. Expected dossier: adapted CTD

Most UEMOA authorities accept (and often require) a CTD-format dossier, structured along the five ICH modules with some regional adaptations.

• Proof of registration in the country of origin (WHO Certificate of Pharmaceutical Product — CPP).
• Manufacturing site opening authorisation and valid GMP certificates.
• Package leaflet and labelling in French, adapted to local storage conditions.
• Stability data in climatic zone IVb (hot and very humid) most often required.
• Proposed selling price and justification, sometimes required to support the dossier.

3. Typical registration steps

• Appointment of a local representative (mandatory in most states).
• Dossier submission to the competent ANRP and payment of fees.
• Administrative acceptability, then scientific evaluation.
• Questions / answers (deficiency letters) where relevant.
• MA decision, publication and entry in the national register.

4. Pitfalls to watch

• Timelines vary between states: plan for 12 to 24 months depending on the authority and product class.
• Documentation requirements evolve: check the version in force before any submission.
• Zone IVb stability is often underestimated by dossiers of European origin.
• Variations and renewals management must be built into the initial strategy.